SUBSCRIBE
SUBSCRIBE

Nick Paul Taylor

Nick is a freelance writer who has been reporting on the global life sciences industry since 2008. With a BSc in biology, Nick writes about the science and business of biopharma and medtech for numerous healthcare publications. He can be reached at nick.paul.taylor@gmail.com or on LinkedIn.

Pictured: Businessmen shaking hands after closing
Business
Stada Bags European Rights from Alvotech to Biosimilar of Amgen Blockbusters
Stada announced Tuesday it has secured European rights from Alvotech to a clinical-stage biosimilar of Amgen’s blockbuster bone drugs Prolia and Xgeva.
June 11, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Pictured: Nasdaq signage and building in New York City
Deals
Alumis Files for IPO to Fund Phase III Trials of Potential Rival Drug to BMS’ Sotyktu
In an SEC filing on Friday, Alumis said it aims to start late-stage trials of a TYK2 inhibitor in plaque psoriasis this year and is seeking public funding for the studies.
June 10, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Pictured: Boehringer Ingelheim's office in California
Drug Development
Boehringer, Zealand’s GLP-1 MASH Data ‘Unintentionally’ Published by Medical Congress Website
Zealand Pharma said on Thursday that partner Boehringer Ingelheim will present the results from the study on Friday at the European Association of the Study of Liver Congress.
June 6, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Pictured: A volcano erupting of damaged and inflamed nerves
Drug Development
Annexon’s Pivotal Phase III GBS Trial Hits Goal, Tees Up Approval Filing
Annexon’s late-stage Guillain-Barré syndrome trial has hit its primary endpoint and laid the foundation for a filing for approval next year, the company said Tuesday.
June 4, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Pictured: Illustration of a human body with the liver highlighted
Drug Development
Tango Stops Early Cancer Trial Over Liver Toxicity, Drops Out of Race Against Roche
Tango Therapeutics reported Thursday that solid tumor patients who stayed in the Phase I study for more than eight weeks developed Grade 3 and 4 liver function abnormalities.
May 23, 2024
 · 
2 min read
 · 
Nick Paul Taylor
AstraZeneca's sign on its office in California
Business
AstraZeneca Snags Option to Buy Versant’s New Obesity Biotech SixPeaks
SixPeaks Bio emerged from stealth Wednesday with up to $110 million, a deal with AstraZeneca and plans to take weight-loss candidates designed to preserve muscle mass toward the clinic.
May 22, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Pictured: GSK's headquarters building in West London
Drug Development
GSK’s Long-Acting Asthma Drug Hits Primary Endpoint in Phase III Trials
Participants experienced fewer asthma attacks when receiving the antibody every six months, GSK said Tuesday, positioning the company to file for approval of the potential blockbuster.
May 21, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Pictured: U.S. Capitol Building, Washington DC
Policy
Sanders Warns Weight-Loss Drugs Could Bankrupt US Healthcare System
A Senate health committee report published Wednesday forecasts spending on prescription drugs to hit $1 trillion a year in 2031, unless the prices of GLP-1 medicines such as Novo Nordisk’s Wegovy are cut.
May 16, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Pictured: Facade of Takeda's office in Massachusetts
Business
Takeda Inks Potential $2.2B Deal for AC Immune’s Alzheimer’s Immunotherapy
Takeda on Monday said it is paying AC Immune $100 million upfront for an option on a Phase Ib/II Alzheimer’s disease candidate that could activate the immune system to clear amyloid beta plaques.
May 13, 2024
 · 
2 min read
 · 
Nick Paul Taylor
AstraZeneca's sign on its office in California
Drug Development
AstraZeneca Invests $140M in Cellectis, Secures 44% Stake in CAR-T Specialist
Cell and gene therapy company Cellectis announced Monday it has completed a $140 million investment from AstraZeneca that extends the biotech’s cash runway into 2026.
May 6, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Pictured: Novartis headquarters in Basel, Switzerl
Deals
Novartis Buys Mariana Oncology in $1B Acquisition, Bolsters Radiopharma Assets
The Swiss drugmaker is paying $1 billion and committing up to $750 million in milestones for Mariana Oncology’s preclinical cancer pipeline and clinical supply capabilities, the companies announced Thursday.
May 2, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Pictured: An hourglass connected by strands of DNA
Drug Development
Prime Medicine Gets FDA Okay for First Trial of Gene Editing Technique
The FDA has cleared a clinical trial of an ex vivo prime editing candidate in patients with a rare disease, Prime Medicine announced Monday. The technique taps CRISPR technology to rewrite defective genes without breaking DNA double helix strands.
April 30, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Pictured: Illustration of cancer cells being held in the crosshairs of a scope
Deals
Ono to Buy Deciphera for $2.4B, Looks to Expand Cancer Pipeline and US Footprint
Ono Pharmaceutical will pay $25.60 per share in an all-cash deal to buy Deciphera Pharmaceuticals for its potential blockbuster oncology drugs and U.S. sales infrastructure, the companies said Monday.
April 29, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Pictured: Regeneron logo on a light brown building
Business
Regeneron Pays Mammoth $100M to Access CRISPR Enzymes for AAV Delivery
Regeneron will use Mammoth Biosciences’ tiny Cas enzymes to deliver in vivo CRISPR-based gene editing therapies to tissues and cell types beyond the liver, the companies announced Thursday.
April 25, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Pictured: Glitchy Human Hand Connecting with Robot
Business
AI-Powered Xaira Launches with $1B, Ex-Genentech Execs Look to Transform R&D
Xaira Therapeutics emerged from stealth on Tuesday with plans to tap the biological equivalent of artificial intelligence image generation tools designed to create molecules that hit hard-to-drug targets.
April 24, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Load More